drugset / Trial / NCT01265667
Trial of CF101 to Treat Patients With Psoriasis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
Timeline
- Start
- 2011-07
- Primary completion
- 2015-03
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Piclidenoson | Small molecule | 2 mg | Oral |